GlassScriptPhysician profile
Destinee Jones
NPI 1063032704
$5,109.00
in general payments reported to CMS, 2019-2025
17 companies · $2,658 in 2025
The $2,658 reported for 2025 was more than what 96% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.67 · 2023: $222 · 2024: $2,216 · 2025: $2,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,067 · Education: $28.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,067.49 |
| Education | $28.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,587.02 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $589.19 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $525.66 | 2023-2025 | Xifaxan, Relistor, Trulance |
| Regeneron Healthcare Solutions, INC. | $505.49 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $373.94 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $359.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $358.19 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $287.58 | 2023-2025 | Entyvio |
| Gilead Sciences, INC. | $171.05 | 2023-2025 | |
| Lilly USA, LLC | $111.07 | 2025 | |
| Celltrion USA INC. | $62.92 | 2024 | Zymfentra |
| Merck Sharp & Dohme LLC | $56.43 | 2023-2024 | Dificid |
| Aimmune Therapeutics, INC. | $33.98 | 2024 | |
| Organogenesis INC. | $29.20 | 2024 | |
| Qol Medical, LLC | $25.49 | 2024 | Sucraid |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $20.07 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Destinee Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.